Roche dumps 4 eye, CNS and cancer drugs in Q4 clear-out

Roche logo

Swiss major Roche announced its financials today, and buried within its pipeline updates the company announced it was dumping a host of early- and late-stage candidates.

In phase 3 it has removed lampalizumab (RG7417), which last fall flopped two tests: Chroma and Spectri, which were assessing the drug in geographic atrophy (GA) due to age-related macular degeneration (AMD), and secondary to AMD.

Jefferies had tipped this drug to top out at $2 billion a year, but it has now been relegated to the Roche dustbin.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

RELATED: Phase 3 fail puts Roche blockbuster-to-be on the critical list

Further back in phase 1 it’s also canning work on two cancer drugs: RG7986, an antibody drug conjugate for refractory B-cell non-Hodgkin’s lymphoma, and RG6047, which was being tested in metastatic estrogen receptor-positive, HER2-negative breast cancer.

The B-cell med had in fact been developed via Seattle Genetics' ADC tech. RG7604, meanwhile, is a small molecule PI3 kinase inhibitor.

And finally, it’s also curtains for RG7203, a small molecule inhibitor of phosphodiesterase 10A (PDE10A) for the treatment of schizophrenia.

RELATED: Roche dumps lead asset from its $725M Seragon buy


Suggested Articles

By employing heart rate signals, physical activity and sleep quality, common Fitbit trackers may be able to predict the spread of the flu.

Nanox has raised $26 million to help fuel the development and commercialization of its Star Trek-inspired digital X-ray bed.

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.